-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Very high-risk (VHR) prostate cancer (PC) is an aggressive subgroup with a high risk of long-range progression in which systematic intensive therapy with abiraterone or docetaxel reduces specific mortality (PCSM) and distal metastases (DM) in men receiving in vitro irradiation radiation therapy (EBRT)
Recently, researchers from Canada published an article in Int J Radiat Oncol Biol Phys investigating
The study cohort came from 16 centers in 4 countries and included men with VHR PC who
The findings suggest that across the cohort, 270 people received EBRT and 101 received EBRT+BT
A specific cause Cox proportional risk model assesses prostate-specific survival and long-distance metastasis
In summary, no clinically significant difference
Original Source:
Sagar A Patel , Ting Martin Ma , Jessica K Wong et al.